.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR24_LamivudineTenofovirDisop.LamivudineTenofovirDisop .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR24_LamivudineTenofovirDisop.LamivudineTenofovirDisop| name: | LamivudineTenofovirDisoproxilAndDoravirine | |
| ATC code: | J05AR24 | route: | oral |
| compartments: | 1 | |
| dosage: | 700 | mg |
| volume of distribution: | 95 | L |
| clearance: | 16.5 | L/h |
| other parameters in model implementation | ||
Fixed-dose combination of antiretrovirals used for the treatment of HIV-1 infection in adults and adolescents. Each drug acts at different steps in the viral lifecycle: lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor (NtRTI), and doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). The combination is approved and used as a complete regimen for HIV management.
Estimated mean pharmacokinetic parameters for healthy adults at steady state following single oral administration of fixed-dose combination tablet containing lamivudine 300mg, tenofovir disoproxil 300mg, and doravirine 100mg.